Skip to main content
Caplight Logo









Anocca

Anocca

Private
Södertälje, Stockholm CountyHealthcare & Life Scienceshttps://www.anocca.com/

Last Round

Early Funding

Aug 18, 2025

Total Funding Raised

$82.65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Anocca is a clinical-stage biopharmaceutical company that develops T-cell receptor-engineered T cell (TCR-T) therapies to treat solid tumours and other diseases. Founded in 2014, the company has a fully integrated platform that includes research and development, a custom software ecosystem (AnoccaOS), and in-house cGMP manufacturing facilities in Södertälje, Sweden. Anocca's proprietary technology aims to scale the development of TCR-T cell therapies, enabling the systematic creation of personalized treatments for broad patient populations. The company is advancing its pipeline, with its lead program, VIDAR-1, in early-stage clinical trials for pancreatic cancer. Anocca is privately held and has received significant venture capital funding from investors including Mellby Gård, AMF, and Ramsbury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

TCR-T therapysolid tumorscell therapyTCR discoverycancer immunotherapyengineered T-cell therapyin-house manufacturingGMP manufacturingprecision oncologyKRAS mutationsautologous cell therapyallogeneic cell therapyoff-the-shelf cell therapyclinical-stage biotechpancreatic cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Anocca Comparables

Compare Anocca with similar companies based on industry and business-model similarity.

Anocca comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enara Bio
83%
ImmunoScape
81%
Affini-T Therapeutics
79%

Anocca Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 18, 2025
Growth EquityMay 31, 2023

Key People

Founding team and executive leadership

Reagan Jarvis

Chief Executive Officer Co-founder

Founding Team

Jacob Michlewicz

Chief Financial Officer

Executive Team

Viktor Arnkil

Chief Operating Officer, Head of Operations

Executive Team

Anocca Investors

Notable investors and investment history

Anocca investors
InvestorRounds
AMF TjänstepensionGrowth Equity
Mellby GårdEarly Funding, Growth Equity
Ramsbury InvestGrowth Equity
Swedbank RoburGrowth Equity
MichanoGrowth Equity
NidocoGrowth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 1070% MoM, reaching 3.4K.

Anocca Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Anocca Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersSödertälje, Stockholm County
Employee Range123
Year Founded2014
Last FundingAug 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?